Literature DB >> 19449206

Neuroprotection against transient focal cerebral ischemia and oxygen-glucose deprivation by interference with GluR6-PSD95 protein interaction.

Chang-Zhou Yu1, Chong Li, Dong-Sheng Pei, Yan-Yan Zong, Qiong Shi, Xiang-Ru Wen, Qiu-Hua Guan, Dong Hang, Xiao-Yu Hou, Guang-Yi Zhang.   

Abstract

Previous studies have shown that KA receptor subunit GluR6 mediated c-Jun N-terminal protein kinase (JNK) signaling is involved in global ischemia injury. Our present study indicates that focal ischemic brain insult on rat middle cerebral artery occlusion (MACo) model enhances the assembly of the GluR6-PSD95-MLK3 module and facilitates the phosphorylation of JNK. Most importantly, a peptide containing the TAT protein transduction sequence, Tat-GluR6-9c, can perturb the assembly of the GluR6-PSD95-MLK3 signaling module and suppress the activation of MLK3, MKK7/4 and JNK. As result, the inhibition of JNK activation caused by Tat-GluR6-9c diminishes the phosphorylation of the transcription factor c-Jun, down-regulates FasL expression and attenuates bax translocation, release of cytochrome c and the activation of caspase-3. Furthermore, MCAo induced infract volume is reduced by intracerebroventricular injection of Tat-Glur6-9c. Oxygen-glucose-deprivation (OGD) cultured cortical neuronal cell also shows an improved cell viability by application of Tat-GluR6-9c. Taken together, our findings strongly suggest that GluR6-PSD95-MLK3 signaling module mediated activation of nuclear and non-nuclear pathways of JNK activation are involved in focal ischemia injury and OGD. Tat-GluR6-9c, the peptide we constructed, gives a new insight into the therapy for ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19449206     DOI: 10.1007/s11064-009-9990-z

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  33 in total

1.  Molecular mechanisms regulating the differential association of kainate receptor subunits with SAP90/PSD-95 and SAP97.

Authors:  S Mehta; H Wu; C C Garner; J Marshall
Journal:  J Biol Chem       Date:  2001-02-20       Impact factor: 5.157

2.  Altered synaptic physiology and reduced susceptibility to kainate-induced seizures in GluR6-deficient mice.

Authors:  C Mulle; A Sailer; I Pérez-Otaño; H Dickinson-Anson; P E Castillo; I Bureau; C Maron; F H Gage; J R Mann; B Bettler; S F Heinemann
Journal:  Nature       Date:  1998-04-09       Impact factor: 49.962

3.  BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak.

Authors:  W X Zong; T Lindsten; A J Ross; G R MacGregor; C B Thompson
Journal:  Genes Dev       Date:  2001-06-15       Impact factor: 11.361

4.  Activation of c-Jun NH2-terminal kinase 3 is mediated by the GluR6.PSD-95.MLK3 signaling module following cerebral ischemia in rat hippocampus.

Authors:  Hui Tian; Quan-Guang Zhang; Guang-Xuan Zhu; Dong-Sheng Pei; Qiu-Hua Guan; Guang-Yi Zhang
Journal:  Brain Res       Date:  2005-11-02       Impact factor: 3.252

5.  The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues.

Authors:  T Lindsten; A J Ross; A King; W X Zong; J C Rathmell; H A Shiels; E Ulrich; K G Waymire; P Mahar; K Frauwirth; Y Chen; M Wei; V M Eng; D M Adelman; M C Simon; A Ma; J A Golden; G Evan; S J Korsmeyer; G R MacGregor; C B Thompson
Journal:  Mol Cell       Date:  2000-12       Impact factor: 17.970

6.  SAP90 binds and clusters kainate receptors causing incomplete desensitization.

Authors:  E P Garcia; S Mehta; L A Blair; D G Wells; J Shang; T Fukushima; J R Fallon; C C Garner; J Marshall
Journal:  Neuron       Date:  1998-10       Impact factor: 17.173

7.  Antioxidant N-acetylcysteine and AMPA/KA receptor antagonist DNQX inhibited mixed lineage kinase-3 activation following cerebral ischemia in rat hippocampus.

Authors:  Hui Tian; Quanguang Zhang; Hongchun Li; Guangyi Zhang
Journal:  Neurosci Res       Date:  2003-09       Impact factor: 3.304

8.  Correlation between cerebral blood flow and histologic changes in a new rat model of middle cerebral artery occlusion.

Authors:  H Nagasawa; K Kogure
Journal:  Stroke       Date:  1989-08       Impact factor: 7.914

9.  Reversible middle cerebral artery occlusion without craniectomy in rats.

Authors:  E Z Longa; P R Weinstein; S Carlson; R Cummins
Journal:  Stroke       Date:  1989-01       Impact factor: 7.914

10.  Bax-deficient mice with lymphoid hyperplasia and male germ cell death.

Authors:  C M Knudson; K S Tung; W G Tourtellotte; G A Brown; S J Korsmeyer
Journal:  Science       Date:  1995-10-06       Impact factor: 47.728

View more
  5 in total

1.  Effective post-insult neuroprotection by a novel Ca(2+)/ calmodulin-dependent protein kinase II (CaMKII) inhibitor.

Authors:  Rebekah S Vest; Heather O'Leary; Steven J Coultrap; Mark S Kindy; K Ulrich Bayer
Journal:  J Biol Chem       Date:  2010-04-27       Impact factor: 5.157

Review 2.  Ras family small GTPase-mediated neuroprotective signaling in stroke.

Authors:  Geng-Xian Shi; Douglas A Andres; Weikang Cai
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2011-06-01

3.  Kalopanacis Cortex extract-capped gold nanoparticles activate NRF2 signaling and ameliorate damage in human neuronal SH-SY5Y cells exposed to oxygen-glucose deprivation and reoxygenation.

Authors:  Sun Young Park; Seon Yeong Chae; Jin Oh Park; Kyu Jin Lee; Geuntae Park
Journal:  Int J Nanomedicine       Date:  2017-06-22

4.  Protective effect of transient receptor potential melastatin 2 inhibitor A10 on oxygen glucose deprivation/reperfusion model.

Authors:  Zhuoqun Huang; Xiafei Yu; Xingyu Liu; Kang Ma; Minghua Huang; Fangfang Li; Wei Yang; Jianguo Niu
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-02-25

5.  Cationic Arginine-Rich Peptides (CARPs): A Novel Class of Neuroprotective Agents With a Multimodal Mechanism of Action.

Authors:  Bruno P Meloni; Frank L Mastaglia; Neville W Knuckey
Journal:  Front Neurol       Date:  2020-02-25       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.